eFFECTOR Therapeutics, Inc. (EFTR)

NASDAQ: EFTR · IEX Real-Time Price · USD
13.32
+1.70 (14.63%)
Feb 27, 2024, 12:52 PM EST - Market open
14.63%
Market Cap 39.70M
Revenue (ttm) 675,000
Net Income (ttm) -35.94M
Shares Out 3.42M
EPS (ttm) -19.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 279,721
Open 11.62
Previous Close 11.62
Day's Range 11.62 - 13.54
52-Week Range 8.45 - 37.00
Beta 0.37
Analysts Strong Buy
Price Target 112.17 (+742.12%)
Earnings Date Mar 6, 2024

About EFTR

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with so... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 15
Stock Exchange NASDAQ
Ticker Symbol EFTR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for EFTR stock is "Strong Buy." The 12-month stock price forecast is $112.17, which is an increase of 742.12% from the latest price.

Price Target
$112.17
(742.12% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (...

22 days ago - GlobeNewsWire

eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regula...

4 weeks ago - GlobeNewsWire

eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regula...

4 weeks ago - GlobeNewsWire

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024

-  Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- -  Review of recently announced interim data from dose escalation and Phase 2 expansion ...

7 weeks ago - GlobeNewsWire

eFFECTOR Therapeutics Announces Reverse Stock Split

EFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024 EFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024

7 weeks ago - GlobeNewsWire

eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients

Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients

2 months ago - GlobeNewsWire

eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer

Designation is for 2 nd or 3 rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor

3 months ago - GlobeNewsWire

eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (...

3 months ago - GlobeNewsWire

eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Management intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium...

3 months ago - GlobeNewsWire

eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (...

4 months ago - GlobeNewsWire

eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia

Trial designed to capitalize on previously published results that showed preclinical activity of tomivosertib in AML models Trial designed to capitalize on previously published results that showed pre...

4 months ago - GlobeNewsWire

eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors ...

6 months ago - GlobeNewsWire

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (...

6 months ago - GlobeNewsWire

eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Positive data update from Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (ZFA triplet) in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) prese...

7 months ago - GlobeNewsWire

eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings

eFFECTOR Closes Second Registered Direct Offering Priced At-The-Market Under Nasdaq Rules eFFECTOR Closes Second Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

9 months ago - GlobeNewsWire

eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (...

9 months ago - GlobeNewsWire

eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (S...

9 months ago - GlobeNewsWire

eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (S...

9 months ago - GlobeNewsWire

eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting

Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib (ZFA triplet) in heavily pretreated population Partial respon...

9 months ago - GlobeNewsWire

eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast Cancer to be presented at the American Society...

10 months ago - GlobeNewsWire

eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“...

10 months ago - GlobeNewsWire

eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer

The Company's eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk patients carrying specific markers predictive ...

11 months ago - GlobeNewsWire

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received zotatif...

1 year ago - GlobeNewsWire

eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI) Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)

1 year ago - GlobeNewsWire